Combined chemotherapy with cyclooxygenase-2 (COX-2) inhibitors in treating human cancers: Recent advancement - 28/08/20
páginas | 10 |
Iconografías | 2 |
Vídeos | 0 |
Otros | 0 |
Graphical abstract |
Highlights |
• | Chemotherapy is standardized treatment of cancers but with unsatisfactory efficacy. |
• | Overexpression of COX-2 is associated with carcinogenesis and cancer progression. |
• | COX-2 inhibitors can exert anti-tumor effects on a variety of cancers. |
• | Such a combination is beneficial to reduce toxicity and chemoresistance and enhance sensitivity. |
• | The review discussed the molecular mechanism of the combinations. |
Abstract |
Chemotherapy with a single chemotherapeutic agent or a combined chemotherapeutic regimen is the clinically standardized treatment for almost all human cancers. Upregulated expression of cyclooxygenase (COX)-2, also known as prostaglandin-endoperoxide synthase (PTGS), is associated with human carcinogenesis and cancer progression and COX-2 inhibitors show antitumor activity in different human cancers. Thus, a combination of chemotherapeutic agents with COX-2 inhibitors has been shown to improve therapeutic effects on human cancers. This review discusses and summarizes recent advances in cancer control and treatment using various antineoplastic drugs combined with COX-2 inhibitors. These combinations showed synergistic antitumor effects. At the gene level, COX-2 inhibitors can reduce inflammatory factors thereby regulating macrophage recruitment for activating the antitumor immune microenvironment; downregulating vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis; and inhibiting the PI3K/Akt signaling pathway to induce tumor cell apoptosis. In addition, such a combination can reduce toxicity and chemoresistance and enhance radiosensitivity, although COX-2 inhibitors-related cardiotoxicity may potentially affect its use. Further in-depth investigation of these drug combinations is needed to maximize antitumor efficacy and minimize the side effects.
El texto completo de este artículo está disponible en PDF.Keywords : Cancer treatment, Chemotherapy, COX-2 inhibitor, Combination medication
Esquema
Vol 129
Artículo 110389- septembre 2020 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?